Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-56021927 DDI Study in Castration-Resistant Prostate Cancer
NCT02592317Phase 1Active, not recruiting
- Sponsor
- Aragon Pharmaceuticals
- Start
- Feb 2016
- Primary completion
- Nov 2016
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of apalutamide in prostate cancer (PCa), sponsored by Aragon Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration at Day 51, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time at Day 51 and 1 more. Started Feb 2016; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02592317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02592317.